{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:00:36Z","timestamp":1791612036544,"version":"4.3.4"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.toxicon.2025.108638","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:52:27Z","timestamp":1761785547000},"page":"108638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications"],"prefix":"10.1016","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-8338","authenticated-orcid":false,"given":"Eqram","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-4746","authenticated-orcid":false,"given":"Alain","family":"Michon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinitha","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2082-2799","authenticated-orcid":false,"given":"Munim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5801-2105","authenticated-orcid":false,"given":"John H.","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woffles TL.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean DA.","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Richard","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2025.108638_bib1","article-title":"Long term outcome for onabotulinumtoxinA (botox) therapy in chronic migraine: a 2-year prospective follow-up audit of patients attending the hull (UK) migraine clinic","volume":"4","author":"Ahmed","year":"2021","journal-title":"Cephalalgia Rep"},{"issue":"3","key":"10.1016\/j.toxicon.2025.108638_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archfaci.6.3.188","article-title":"Botulinum toxin for masseter reduction in Asian patients","volume":"6","author":"Ahn","year":"2004","journal-title":"Arch. Facial Plast. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107220","article-title":"GLP\u20101 receptor agonists for Parkinson's disease: an updated meta-analysis","volume":"130","author":"Albuquerque","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.toxicon.2025.108638_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.toxicon.2025.108638_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/ane.12171","article-title":"OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program","volume":"129","author":"Aurora","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.toxicon.2025.108638_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2025.108638_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"10.1016\/j.toxicon.2025.108638_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2022.03.032","article-title":"The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis","author":"Avogaro","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.toxicon.2025.108638_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","author":"Baggio","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.toxicon.2025.108638_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/ar.24756","article-title":"Botulinum toxin in the masseter muscle: lingering effects of denervation","volume":"305","author":"Baldwin","year":"2022","journal-title":"Anat. Rec."},{"key":"10.1016\/j.toxicon.2025.108638_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2018.11.035","article-title":"Safety and efficacy of onabotulinumtoxinA for treatment of masseter muscle hypertrophy: results from a phase 2 dose-escalation study","volume":"156","author":"Brin","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2025.108638_bib12","series-title":"Advanced Techniques in Dermatologic Surgery","article-title":"Advanced cosmetic use of botulinum toxin type A","author":"Carruthers","year":"2006"},{"key":"10.1016\/j.toxicon.2025.108638_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaad.2024.10.064","article-title":"Reduction of masseter muscle prominence after treatment with onabotulinumtoxinA: primary results from a randomized phase 2 study","volume":"92","author":"Carruthers","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxicon.2025.108638_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaad.2024.10.064","article-title":"Reduction of masseter muscle prominence after treatment with onabotulinumtoxinA: primary results from a randomized phase 2 study","volume":"92","author":"Carruthers","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxicon.2025.108638_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13177","article-title":"GLP-1 agonists for obesity and type 2 diabetes in children: systematic review and meta-analysis","volume":"22","author":"Chadda","year":"2021","journal-title":"Obes. Rev."},{"key":"10.1016\/j.toxicon.2025.108638_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.793004","article-title":"GLP-1 suppresses feeding behaviors and modulates neuronal electrophysiological properties in multiple brain regions","author":"Chen","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.toxicon.2025.108638_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000001859","article-title":"Botulinum toxin injections for masseter reduction in east Asians","author":"Cheng","year":"2019","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/toxins13010058","article-title":"Botulinum toxin: an update on pharmacology and newer products in development","volume":"13","author":"Choudhury","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108638_bib19","series-title":"Guideline on the Reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation","year":"2018"},{"key":"10.1016\/j.toxicon.2025.108638_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork","year":"2015","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.toxicon.2025.108638_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105385","article-title":"Making in silico predictive models for toxicology FAIR","volume":"140","author":"Cronin","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.toxicon.2025.108638_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.comtox.2022.100213","article-title":"A review of in silico toxicology approaches to support the safety assessment of cosmetics-related materials","volume":"21","author":"Cronin","year":"2022","journal-title":"Computational Toxicology"},{"key":"10.1016\/j.toxicon.2025.108638_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/asjof\/ojaf056","article-title":"\u201cOzempic Face\u201d in plastic surgery: a systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions","volume":"7","author":"Daneshgaran","year":"2025","journal-title":"Aesthet Surg J Open Forum"},{"key":"10.1016\/j.toxicon.2025.108638_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65395-5","article-title":"Exploring botulinum toxin's impact on masseter hypertrophy: a randomized, triple-blinded clinical trial","volume":"14","author":"de Souza Nobre","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxicon.2025.108638_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2025.108638_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/0333102418825382","article-title":"Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: analysis of PREEMPT data","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.toxicon.2025.108638_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","article-title":"The global burden of migraine: a 30-Year trend review and future projections by age, sex, country, and region","volume":"14","author":"Dong","year":"2025","journal-title":"Pain Ther"},{"key":"10.1016\/j.toxicon.2025.108638_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2022.06.676","article-title":"34952 efficacy and safety of 2 doses of onabotulinumtoxin A for the treatment of masseter muscle prominence: 6-Month results from a randomized, phase 2b placebo-controlled study","volume":"87","author":"Fabi","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.toxicon.2025.108638_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s00429-020-02189-1","article-title":"Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain","volume":"226","author":"Farkas","year":"2021","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.toxicon.2025.108638_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152869","article-title":"Pancreatic beta cell G-protein coupled receptors and second messenger interactions: a systems biology computational analysis","author":"Fridlyand","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.toxicon.2025.108638_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13001","article-title":"Recent new insights into the role of SNARE and associated proteins in insulin granule exocytosis","author":"Gaisano","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.toxicon.2025.108638_bib97","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/cpt.3245","article-title":"Considerations for Industry\u2014Preparing for the FDA Model\u2010Informed Drug Development (MIDD) Paired Meeting Program","volume":"116","author":"Galluppi","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.toxicon.2025.108638_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2015.12.014","article-title":"Differential role of SNAP-25 phosphorylation by protein kinases A and C in the regulation of SNARE complex formation and exocytosis in PC12 cells","volume":"28","author":"Gao","year":"2016","journal-title":"Cell. Signal."},{"key":"10.1016\/j.toxicon.2025.108638_bib33","doi-asserted-by":"crossref","DOI":"10.1046\/j.1471-4159.1999.721699.x","article-title":"Activity-dependent phosphorylation of SNAP-25 in hippocampal organotypic cultures","volume":"72","author":"Genoud","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.toxicon.2025.108638_bib34","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.toxicon.2025.108638_bib35","article-title":"Phosphorylation of SNAP-25 on serine-187 is induced by secretagogues in insulin-secreting cells, but is not correlated with insulin secretion","volume":"368","author":"Gonelle-Gispert","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.toxicon.2025.108638_bib36","doi-asserted-by":"crossref","DOI":"10.1091\/mbc.9.3.585","article-title":"SNAP-25 palmitoylation and plasma membrane targeting require a functional secretory pathway","volume":"9","author":"Gonzalo","year":"1998","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.toxicon.2025.108638_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2016.11.007","article-title":"Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes","volume":"27","author":"Gorgojo-Mart\u00ednez","year":"2017","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.toxicon.2025.108638_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.998816","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a bayesian network meta-analysis","author":"Guan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.toxicon.2025.108638_bib39","article-title":"Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes","volume":"3","author":"Gutierrez","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.toxicon.2025.108638_bib40","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1055\/s-0044-1785450","article-title":"Letter to the editor: comment on implications of ozempic and other semaglutide medications for facial plastic surgeons","volume":"39","author":"Hansen","year":"2023","journal-title":"Facial Plast. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/a-2148-6321","article-title":"Implications of ozempic and other semaglutide medications for facial plastic surgeons","volume":"39","author":"Humphrey","year":"2023","journal-title":"Facial Plast. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib42","article-title":"Global diabetes data report 2010-2045","volume":"9","year":"2019","journal-title":"Journal IDF 9\u00b0 edithion"},{"key":"10.1016\/j.toxicon.2025.108638_bib43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon\u2010like peptide 1 receptor\u2010based agonist: a meta\u2010analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.toxicon.2025.108638_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.toxicon.2025.108638_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/minf.201400137","article-title":"Establishing Good Computer Modelling Practice (GCMP) in the prediction of chemical toxicity","volume":"34","author":"Judson","year":"2015","journal-title":"Mol Inform"},{"key":"10.1016\/j.toxicon.2025.108638_bib46","doi-asserted-by":"crossref","DOI":"10.31083\/j.rcm2204152","article-title":"Cardiovascular outcomes of glucose lowering therapy in chronic kidney disease patients: a systematic review with meta-analysis","author":"Kamdar","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.toxicon.2025.108638_bib47","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.toxicon.2025.108638_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108737","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis","author":"Karagiannis","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.toxicon.2025.108638_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/phar.2737","article-title":"Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis","author":"Kelly","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.toxicon.2025.108638_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/1129-2377-15-54","article-title":"Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK","volume":"15","author":"Khalil","year":"2014","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2025.108638_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-4632.2010.04821.x","article-title":"Botulinum toxin historical aspects: from food poisoning to pharmaceutical","volume":"50","author":"Kopera","year":"2011","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.toxicon.2025.108638_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/diseases12010014","article-title":"Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis","author":"Krisanapan","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.toxicon.2025.108638_bib53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/toxins9010014","article-title":"The anatomical basis of paradoxical masseteric bulging after botulinum Neurotoxin type A injection","volume":"9","author":"Lee","year":"2016","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108638_bib54","doi-asserted-by":"crossref","first-page":"910e","DOI":"10.1097\/PRS.0000000000010840","article-title":"A multicenter phase II Study evaluating the safety and efficacy of Botulax in Asian patients with benign masseteric hypertrophy","volume":"153","author":"Lee","year":"2024","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/febs.13785","article-title":"Glucagon-like peptide-1 drives energy metabolism on the synaptic highway","author":"Liu","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.toxicon.2025.108638_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajcnut.2023.04.017","article-title":"The weight-loss effect of GLP-1 RAs Glucagon-Like Peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials","volume":"118","author":"Liu","year":"2023","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.toxicon.2025.108638_bib57","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","article-title":"Review: role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making","volume":"39","author":"Madabushi","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.toxicon.2025.108638_bib58","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","author":"Mahapatra","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.toxicon.2025.108638_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.678055","article-title":"The interplay of glucagon-like Peptide-1 receptor trafficking and signalling in pancreatic beta cells","author":"Marzook","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.toxicon.2025.108638_bib60","series-title":"Pandas-Powerful Python Data Analysis Toolkit","author":"McKinney","year":"2015"},{"key":"10.1016\/j.toxicon.2025.108638_bib61","doi-asserted-by":"crossref","DOI":"10.1111\/head.12038","article-title":"Contributions of epidemiology to our understanding of migraine","author":"Merikangas","year":"2013","journal-title":"Headache"},{"key":"10.1016\/j.toxicon.2025.108638_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon\u2010like peptide\u20101\u2010based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.toxicon.2025.108638_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/s40122-021-00328-y","article-title":"Is there a gender difference in the response to onabotulinumtoxinA in chronic migraine? Insights from a real-life European multicenter Study on 2879 patients","volume":"10","author":"Ornello","year":"2021","journal-title":"Pain Ther"},{"key":"10.1016\/j.toxicon.2025.108638_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/medicines9090047","article-title":"The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly Obese diabetic patients: a pilot Study","volume":"9","author":"Ozeki","year":"2022","journal-title":"Medicines"},{"key":"10.1016\/j.toxicon.2025.108638_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/bph.12313","article-title":"Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation","author":"Pabreja","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.toxicon.2025.108638_bib66","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"The BMJ"},{"key":"10.1016\/j.toxicon.2025.108638_bib67","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.3519-06.2006","article-title":"Synaptotagmin-2 is essential for survival and contributes to Ca 2+ triggering of neurotransmitter release in central and neuromuscular synapses","volume":"26","author":"Pang","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.toxicon.2025.108638_bib68","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-Like peptide 1 receptor agonists and mental health","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.toxicon.2025.108638_bib69","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-023-00431-2","article-title":"Synaptic retrograde regulation of the PKA-induced SNAP-25 and Synapsin-1 phosphorylation","volume":"28","author":"Polishchuk","year":"2023","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.toxicon.2025.108638_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2023.12.014","article-title":"Use of dulaglutide, semaglutide, and tirzepatide in diabetes and weight management","volume":"46","author":"Powell","year":"2024","journal-title":"Clin. Ther."},{"key":"10.1016\/j.toxicon.2025.108638_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108560","article-title":"Targeting the glabellar frown lines with OnabotulinumtoxinA: In-Silico evidence supporting concentrated, low-volume injection protocols","author":"Rahman","year":"2025","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2025.108638_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2025.108548","article-title":"In Silico Multiscale computational modelling of botulinum toxin A diffusion for glabellar wrinkle treatment: optimizing injection volumes across formulations","author":"Rahman","year":"2025","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2025.108638_bib73","article-title":"Predictive modelling of immunogenicity to Botulinumtoxin A treatments for glabellar lines","author":"Rahman","year":"2024","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib74","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00238-025-02311-8","article-title":"In silico multiscale comparison of LetibotulinumtoxinA and OnabotulinumtoxinA in glabellar line treatment: diffusion dynamics, receptor affinity, and immunologic clearance","volume":"48","author":"Rahman","year":"2025","journal-title":"Eur. J. Plast. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib75","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/toxins17040182","article-title":"Computational immunogenetic analysis of botulinum toxin A immunogenicity and HLA gene haplotypes: new insights","volume":"17","author":"Rahman","year":"2025","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108638_bib76","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00238-025-02331-4","article-title":"Beyond binary endpoints: modernizing aesthetic trial analytics: Simulation-Based reappraisal of phase 2\/3 BoNT-A studies using advanced statistical models","volume":"48","author":"Rahman","year":"2025","journal-title":"Eur. J. Plast. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib77","article-title":"Disruptions in aesthetic medicine: a global analysis of GLP-1 agonists using punctuated equilibrium framework","author":"Rahman","year":"2025","journal-title":"Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib78","doi-asserted-by":"crossref","DOI":"10.1007\/s00266-025-04924-7","article-title":"Frontalis only contracts in one direction: AI\u2013Quantum elasticity and resistance gradient reveals true Nature of Forehead muscle movement","author":"Rahman","year":"2025","journal-title":"Aesthetic Plast. Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib79","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2006.01438.x","article-title":"Pharmacology of botulinum toxin: differences between type A preparations","volume":"13","author":"Rosales","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2025.108638_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.toxicon.2025.108638_bib81","article-title":"Semaglutide, popularly known as Ozempic\u2014What the facial plastic surgeon needs to know","author":"Sciscent","year":"2024","journal-title":"Facial Plast Surg Aesthet Med"},{"key":"10.1016\/j.toxicon.2025.108638_bib82","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.2352-07.2008","article-title":"Phosphorylation of SNAP-25 at Ser 187 mediates enhancement of exocytosis by a phorbol ester in INS-1 cells","volume":"28","author":"Shu","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.toxicon.2025.108638_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13611","article-title":"Glucose-induced cAMP elevation in \u03b2-cells involves amplification of constitutive and glucagon-activated GLP-1 receptor signalling","volume":"231","author":"Shuai","year":"2021","journal-title":"Acta Physiol."},{"key":"10.1016\/j.toxicon.2025.108638_bib84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","article-title":"The origin, structure, and pharmacological activity of botulinum toxin","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.toxicon.2025.108638_bib85","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-022-00914-3","article-title":"Activation of arcuate nucleus glucagon-like peptide-1 receptor-expressing neurons suppresses food intake","volume":"12","author":"Singh","year":"2022","journal-title":"Cell Biosci."},{"key":"10.1016\/j.toxicon.2025.108638_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/toxins7072659","article-title":"Treatment of chronic migraine with OnabotulinumtoxinA: mode of action, efficacy and safety","author":"Szok","year":"2015","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2025.108638_bib87","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.18306","article-title":"Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies","volume":"71","author":"Tang","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.toxicon.2025.108638_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjps.2023.04.057","article-title":"Ozempic face: a new challenge for facial plastic surgeons","author":"Tay","year":"2023","journal-title":"J. Plast. Reconstr. Aesthetic Surg."},{"key":"10.1016\/j.toxicon.2025.108638_bib89","series-title":"National Health Statistics Reports","year":"2023"},{"key":"10.1016\/j.toxicon.2025.108638_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255726","article-title":"GLP-1 and GIP receptor agonists in the treatment of Parkinson's disease: translational systematic review and meta-analysis protocol of clinical and preclinical studies","author":"Vaccari","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.toxicon.2025.108638_bib91","doi-asserted-by":"crossref","DOI":"10.1109\/MCSE.2011.37","article-title":"The NumPy array: a structure for efficient numerical computation","volume":"13","author":"Van Der Walt","year":"2011","journal-title":"Comput. Sci. Eng."},{"key":"10.1016\/j.toxicon.2025.108638_bib92","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxicon.2025.108638_bib93","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1513004112","article-title":"Synaptotagmin-7 phosphorylation mediates GLP-1-dependent potentiation of insulin secretion from \u03b2-cells","volume":"112","author":"Wu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.toxicon.2025.108638_bib94","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-022-02742-x","article-title":"OnabotulinumtoxinA in chronic migraine: is the response dose dependent?","volume":"22","author":"Zandieh","year":"2022","journal-title":"BMC Neurol."},{"key":"10.1016\/j.toxicon.2025.108638_bib95","doi-asserted-by":"crossref","DOI":"10.1006\/bbrc.1997.7286","article-title":"SNAP-25 is phosphorylated by glucose and GLP-1 in RIN 1046-38 cells","volume":"238","author":"Zhou","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.toxicon.2025.108638_bib96","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-023-01198-4","article-title":"Efficacy and safety of tirzepatide, dual GLP-1\/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","author":"Zhou","year":"2023","journal-title":"Diabetol. Metab. Syndr."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010125004131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010125004131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T04:56:50Z","timestamp":1770008210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010125004131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":97,"alternative-id":["S0041010125004131"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2025.108638","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2025.108638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108638"}}